Comparing Efficacy and Safety of Inhaled SNG001 to Placebo

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Synairgen Research Ltd.
ClinicalTrials.gov Identifier:
NCT01126177
First received: May 17, 2010
Last updated: February 10, 2012
Last verified: February 2012
  Purpose

When people with asthma get respiratory virus such as a cold or flu it often increases asthma symptoms. The investigators will test the study medication to find out if it can prevent the virus spreading from the nose to the lungs.

SNG001 contains Interferon-beta that occurs naturally in the body. In this study, SNG001 will be given by a nebuliser.


Condition Intervention Phase
Asthma
Drug: Interferon beta 1a
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomised, Double-blind, Placebo-controlled Phase II Study, Comparing the Efficacy and Safety of Inhaled SNG001 to Placebo Administered to Asthmatic Subjects After the Onset of a Respiratory Viral Infection for the Prevention or Attenuation of Asthma Symptoms Caused by Respiratory Viruses

Resource links provided by NLM:


Further study details as provided by Synairgen Research Ltd.:

Primary Outcome Measures:
  • S-ACQ [ Time Frame: Baseline - Day 8 ] [ Designated as safety issue: Yes ]

    To evaluate the superiority of inhaled SNG001 compared to placebo administered to asthmatic subjects after the onset of a respiratory viral infection for the prevention or attenuation of asthma symptoms caused by respiratory viruses in the modified intention to treat (mITT) population as measured by change from Baseline to Day 8 in the Shortened-Asthma Control Questionnaire (symptoms plus short-acting β2 agonist.

    - change from Baseline to Day 8 in the Shortened-Asthma Control Questionnaire



Secondary Outcome Measures:
  • Asthma Index [ Time Frame: Day 1-14 ] [ Designated as safety issue: Yes ]
    To evaluate the superiority of inhaled SNG001 compared to placebo administered to asthmatic subjects after the onset of a respiratory viral infection for the prevention or attenuation of asthma symptoms caused by respiratory viruses in the mITT population as measured by peak score of the Asthma Index (Sorkness et al, 2008) in the 14 day period following first administration of study drug (measured from 24 hours post first dose to 24 hours post last dose taken).

  • S-ACQ [ Time Frame: Baseline - Day 8 ] [ Designated as safety issue: Yes ]
    To evaluate the superiority of inhaled SNG001 compared to placebo administered to asthmatic subjects after the onset of a respiratory viral infection for the prevention or attenuation of asthma symptoms caused by respiratory viruses in the per protocol (PP) population as measured by change from Baseline to Day 8 in the Shortened-Asthma Control Questionnaire.

  • Asthma Index [ Time Frame: 14 days ] [ Designated as safety issue: Yes ]
    To evaluate the superiority of inhaled SNG001 compared to placebo administered to asthmatic subjects after the onset of a respiratory viral infection for the prevention or attenuation of asthma symptoms caused by respiratory viruses in the PP population as measured by peak score of the Asthma Index in the 14 day period following first administration of study drug (measured from 24 hours post first dose to 24 hours post last dose taken).

  • Sever Exacerbation [ Time Frame: Day 1-14 ] [ Designated as safety issue: Yes ]
    To evaluate the superiority of inhaled SNG001 compared to placebo administered to asthmatic subjects after the onset of a respiratory viral infection for the prevention or attenuation of asthma symptoms caused by respiratory viruses as measured by the proportion of subjects experiencing a severe exacerbation (Appendix 2) in the mITT population during the 14 days following first administration of study drug.

  • Lung Function [ Time Frame: Day 1-14 ] [ Designated as safety issue: Yes ]
    To compare inhaled SNG001 to placebo administered to asthmatic subjects after the onset of a respiratory viral infection for the prevention or attenuation of decreases in lung function (AUC FEV1 and PEFR) caused by respiratory viruses in the mITT population during the 14 day dosing period.

  • Viral Load [ Time Frame: Days 4 and 7 ] [ Designated as safety issue: Yes ]
    To compare the effect of inhaled SNG001 to placebo when administered to asthmatic subjects on viral load on Days 4 and 7 in sputum.

  • Safety [ Time Frame: Day 1-14 ] [ Designated as safety issue: Yes ]
    To evaluate the safety of inhaled SNG001 when administered to asthmatic subjects.

  • Concomitant Medications [ Time Frame: Day 1-28 ] [ Designated as safety issue: Yes ]
    To compare the frequency of use of concomitant medications in relation to conditions of the respiratory tract during the study Treatment Phase in asthmatic subjects receiving inhaled SNG001 compared to placebo.

  • Pharmacokinetic [ Time Frame: Day 1-14 ] [ Designated as safety issue: Yes ]
    To gain information on the pharmacokinetic profile of inhaled SNG001 administered to asthmatic subjects during a respiratory virus infection.

  • Pharmacodynamic [ Time Frame: Day 1-14 ] [ Designated as safety issue: Yes ]
    To gain information on the pharmacodynamic profile of inhaled SNG001 administered to asthmatic subjects during a respiratory virus infection.


Enrollment: 300
Study Start Date: March 2010
Study Completion Date: January 2012
Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
Placebo once daily for 14 days
Drug: Placebo
Placebo (excipients of the SNG001 solution only)
Experimental: SNG001 Drug: Interferon beta 1a
SNG001, IFN-β1a solution for inhalation

Detailed Description:

The study will consist of a Pre-Treatment Phase into which subjects potentially eligible for the Treatment Phase will be recruited. Subjects will remain in the Pre-Treatment Phase until they experience respiratory virus symptoms at which time they will be further screened for eligibility for entry into the Treatment Phase. If eligible, subjects will be randomised 1:1 to receive SNG001 or placebo once daily for 14 days. Doses will be delivered by a CE marked breath actuated nebuliser (I-neb Philips Respironics). Subjects will be assessed for changes in changes in respiratory virus symptoms and asthma symptoms at home using a text message system, and via telephone questionnaire. Lung function will be measured both at home by the subjects (PEFR only) and in the clinic. Efficacy and safety will be monitored until at least 30 days post treatment.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria
  1. Male or female aged 18 to 65 years of age at the time of screening.
  2. Symptoms of asthma for at least 2 years pri or to the Screening Visit, confirmed by a medical history and:

    1. ≥12% and 200mL bronchodilator reversibility at screening or documented in the past, OR,
    2. evidence of bronchial hyper-responsiveness at screening or documented in the past, OR,
    3. a documented hospital admission (including an Accident and Emergency admission) for asthma since the age of 18, OR.
    4. documented evidence that they have attended their GP surgery, out-of-hours clinic (or alternative health care provider) for worsening of asthma symptoms, since the age of 18
  3. Must answer "Yes‟ to the question "Does a cold make your asthma worse?"
  4. To have had at least one asthma exacerbation suspected to have been caused by a respiratory virus in the last 24 months which required the use of oral steroids and/or additional treatment with antibiotics on one or more occasion.
  5. Must be taking regular inhaled corticosteroids.
  6. Pre-bronchodilator FEV1 ≥ 40 % predicted at screening.
  7. Post-bronchodilator FEV1 ≥ 50 % predicted at screening.
  8. Provide written informed consent.
  9. Females of childbearing potential must be using a medically acceptable adequate form of birth control and agree to maintain this usage throughout the duration of and four weeks post the Treatment Phase of the study.
  10. Motivation (in the Investigator‟s opinion) to complete all study visits, the ability to communicate well with the Investigator and be capable of understanding the nature of the research and its treatment including its risks and benefits.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01126177

Locations
United Kingdom
Southampton University General Hospital
Southampton, Hampshire, United Kingdom, SO16 6YD
Sponsors and Collaborators
Synairgen Research Ltd.
Investigators
Principal Investigator: Ratko Djukanovic, MD, DM, FRCP University of Southampton
  More Information

Additional Information:
No publications provided

Responsible Party: Synairgen Research Ltd.
ClinicalTrials.gov Identifier: NCT01126177     History of Changes
Other Study ID Numbers: SG005
Study First Received: May 17, 2010
Last Updated: February 10, 2012
Health Authority: United States: Food and Drug Administration
United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by Synairgen Research Ltd.:
asthma

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Interferon-beta
Interferons
Interferon beta 1a
Antiviral Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Immunologic Factors
Physiological Effects of Drugs
Antineoplastic Agents
Adjuvants, Immunologic

ClinicalTrials.gov processed this record on April 15, 2014